(NASDAQ:CBMX)(NASDAQ:ACTG)CombiMatrix Molecular Diagnostics Receives CLIA Certification
NEWPORT BEACH, Calif.--(Business Wire)--March 31, 2006--
Acacia Research Corporation (NASDAQ:CBMX)(NASDAQ:ACTG)
announced today its CombiMatrix group's wholly-owned subsidiary,
CombiMatrix Molecular Diagnostics (CMDX), has received certification
to operate as a clinical laboratory in accordance with the federal
government's Clinical Laboratory Improvement Act (CLIA), a regulatory
program that monitors the quality of laboratory testing. According to
CLIA, any laboratory in the U.S. that conducts testing on human
specimens for purposes other than research must be certified.
"This is an important milestone for our company," said Matt
Watson, CEO of CMDX. "Since opening our doors in May of 2005 we have
been working diligently to establish a program of processes and
procedures that would meet CLIA's strict quality control and quality
assurance standards. Now that we have met those standards we are
cleared to begin offering high quality clinical testing services at
our state-of-the-art laboratory in Irvine, California."
Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: 425-493-2010
Copyright Business Wire 2006
31Mar06 11:01 GMT
Symbols:
de;AZG de;AZGF de;AZGX us;ACTG us;CBMX
Source BW Business Wire
